NASDAQ: OXBROxbridge Re Holdings Ltd Stock
$1.37-0.07 (-4.86%)
Updated Apr 21, 2025
OXBR Price
$1.37
Fair Value Price
$0.26
Market Cap
$10.20M
52 Week Low
$1.00
52 Week High
$5.81
P/E
-3.04x
P/B
2.58x
P/S
8.82x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.85M
Earnings
-$2.73M
Gross Margin
91.1%
Operating Margin
-95.68%
Profit Margin
-95.7%
Debt to Equity
0.85
Operating Cash Flow
-$1M
Beta
0.9
Next Earnings
May 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
OXBR Overview
Oxbridge Re Holdings Limited, together with its subsidiaries, provides specialty property and casualty reinsurance solutions. It underwrites reinsurance contracts primarily for property and casualty insurance companies in the Gulf Coast region of the United States. The company distributes its products and solutions through reinsurance brokers. Oxbridge Re Holdings Limited was incorporated in 2013 and is headquartered in George Town, the Cayman Islands.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine OXBR's potential to beat the market
- OXBR doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Reinsurance Insurance
Industry Rating
D
OXBR
RankedUnranked of 8
RankedUnranked of 8
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $48.02 | C | |
| $342.87 | C | |
| $15.99 | C |
Be the first to know about important OXBR news, forecast changes, insider trades & much more!
OXBR News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how OXBR scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
OXBR ($1.37) is overvalued by 421.34% relative to our estimate of its Fair Value price of $0.26 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
OXBR ($1.37) is not significantly undervalued (421.34%) relative to our estimate of its Fair Value price of $0.26 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
OXBR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more OXBR due diligence checks available for Premium users.
Valuation
OXBR fair value
Fair Value of OXBR stock based on Discounted Cash Flow (DCF)
Price
$1.37
Fair Value
$0.26
Overvalued by
421.34%
OXBR ($1.37) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
OXBR ($1.37) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
OXBR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
OXBR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.04x
Industry
10.04x
Market
27.14x
OXBR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.58x
Industry
1.05x
OXBR is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
OXBR's financial health
Profit margin
Revenue
$2.7M
Net Income
-$460.0k
Profit Margin
-16.9%
OXBR's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$7.5M
Liabilities
$3.4M
Debt to equity
0.85
OXBR's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
OXBR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$16.0k
Investing
$332.0k
Financing
$724.0k
OXBR vs Reinsurance Insurance Stocks
Oxbridge Re Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.